AR089852A1 - Anticuerpos anti-asic-1 y usos de los mismos - Google Patents

Anticuerpos anti-asic-1 y usos de los mismos

Info

Publication number
AR089852A1
AR089852A1 ARP130100280A AR089852A1 AR 089852 A1 AR089852 A1 AR 089852A1 AR P130100280 A ARP130100280 A AR P130100280A AR 089852 A1 AR089852 A1 AR 089852A1
Authority
AR
Argentina
Prior art keywords
antibodies
asic1
acid
cells expressing
asic
Prior art date
Application number
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47666522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR089852(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of AR089852A1 publication Critical patent/AR089852A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente proporciona anticuerpos y fragmentos de unión a antígeno de los mismos que se unen específicamente a células que expresan el canal iónico sensible al ácido de tipo 1 (ASIC1). De acuerdo con ciertas realizaciones, los anticuerpos inhiben las corrientes iónicas mediadas por ASIC1, inducidas por ácido en células que expresan ASIC1 humana. Los anticuerpos son útiles para el tratamiento del dolor, incluyendo el dolor asociado con intervenciones quirúrgicas y diversas enfermedades y trastornos.
ARP130100280 2012-01-31 2013-01-30 Anticuerpos anti-asic-1 y usos de los mismos AR089852A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261592837P 2012-01-31 2012-01-31
US201261644038P 2012-05-08 2012-05-08
US201261692925P 2012-08-24 2012-08-24

Publications (1)

Publication Number Publication Date
AR089852A1 true AR089852A1 (es) 2014-09-24

Family

ID=47666522

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100280 AR089852A1 (es) 2012-01-31 2013-01-30 Anticuerpos anti-asic-1 y usos de los mismos

Country Status (33)

Country Link
US (3) US9150648B2 (es)
EP (2) EP3453723B1 (es)
JP (1) JP6302844B2 (es)
KR (1) KR102111941B1 (es)
CN (1) CN104093738B (es)
AR (1) AR089852A1 (es)
AU (1) AU2013215254B2 (es)
CA (1) CA2862332C (es)
CL (1) CL2014002019A1 (es)
CO (1) CO7020877A2 (es)
CY (2) CY1121368T1 (es)
DK (2) DK2809681T3 (es)
EA (1) EA028647B1 (es)
ES (2) ES2886123T3 (es)
HK (1) HK1199269A1 (es)
HR (2) HRP20211541T1 (es)
HU (2) HUE042531T2 (es)
IL (2) IL233410A0 (es)
IN (1) IN2014CN04645A (es)
JO (1) JO3547B1 (es)
LT (2) LT3453723T (es)
MX (1) MX358518B (es)
MY (1) MY168748A (es)
NZ (1) NZ626242A (es)
PH (1) PH12014501613B1 (es)
PL (2) PL2809681T3 (es)
PT (2) PT2809681T (es)
RS (2) RS58439B1 (es)
SG (1) SG11201403222UA (es)
SI (2) SI3453723T1 (es)
TW (1) TWI591073B (es)
UY (1) UY34603A (es)
WO (1) WO2013116296A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA028647B1 (ru) 2012-01-31 2017-12-29 Ридженерон Фармасьютикалз, Инк. Антитела к asic1 и их применение
AU2015247742A1 (en) 2014-04-15 2016-11-24 Sorrento Therapeutics, Inc. Antigen binding proteins that bind WISP1
ES2815572T3 (es) * 2014-05-16 2021-03-30 Ablynx Nv Dominios variables de inmunoglobulina
CN105233286B (zh) * 2015-09-10 2018-10-30 上海交通大学医学院 含酸敏感离子通道调控剂的制剂及其在治疗瘙痒中的用途
CN105713089B (zh) * 2016-02-26 2019-08-06 上海科技大学 一种特异性抑制酸敏感离子通道i型的全人抗体
WO2018085441A1 (en) * 2016-11-01 2018-05-11 Berg Llc Filamin b binding proteins and uses thereof
JP2021511058A (ja) * 2018-01-26 2021-05-06 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ｔｍｐｒｓｓ２抗体および抗原結合断片
WO2020243912A1 (en) * 2019-06-04 2020-12-10 Shanghaitech University AFFINITY-MATURATED ANTI-ASIC1a ANTIBODIES
WO2021007371A1 (en) * 2019-07-11 2021-01-14 Memorial Sloan Kettering Cancer Center Dll3-targeting antibodies and uses thereof
AU2019457621A1 (en) * 2019-07-23 2022-02-17 Shanghaitech University ASIC1 channel antagonist antibody
CN114641503A (zh) * 2019-09-13 2022-06-17 纪念斯隆-凯特琳癌症中心 抗cd371抗体及其用途
EP4384218A2 (en) * 2021-08-09 2024-06-19 Merck Patent GmbH Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokines
CA3230628A1 (en) * 2021-09-02 2023-03-09 John T. POIRIER Anti-dll3 antibodies and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2759373B1 (fr) 1997-02-11 2001-05-04 Centre Nat Rech Scient Nouveau canal cationique neuronal de mammifere sensible a l'acidite, son clonage et ses applications
DE69836591T2 (de) 1997-10-29 2007-09-20 Mcgill University, Montreal Dna kodierend für einen humanen protonenabhängigen ionenkanal und deren verwendungen
US6287859B1 (en) 1998-08-05 2001-09-11 Centre National De La Recherche Identification, functional expression and chromosal localization of a sustained human proton-gated cation channel
CA2304494A1 (en) 2000-04-20 2001-10-20 Philippe Seguela A novel heteromultimeric ion channel receptor and uses thereof
US6635432B1 (en) 2000-04-25 2003-10-21 University Of Iowa Research Foundation Peptide potentiation of acid-sensory ion channel in pain
US7132505B1 (en) 2001-05-10 2006-11-07 Centre National De La Recherche Scientifique - Cnrs Polypeptide inhibiting a proton-gated Na+ channel, a nucleic acid coding for such polypeptide and a method of manufacturing an ASIC1a channel blocker
CA2352702A1 (en) * 2001-07-18 2003-01-18 Philippe Seguela Novel human proton gated ion channel
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
MXPA04009418A (es) * 2002-03-29 2005-06-08 Schering Corp Anticuerpos monoclonales humanos par interleucina-5, y metodos y composiciones que comprenden los mismos.
US20030186860A1 (en) 2002-03-29 2003-10-02 Welsh Michael J. Novel compositions and methods for modulating the acid-sensing ion channel (ASIC)
US20070197583A1 (en) 2002-03-29 2007-08-23 Welsh Michael J Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction
US20070092444A1 (en) * 2003-09-11 2007-04-26 The Uab Research Foundation Inhibition of inward sodium currents in cancer
US20070281986A1 (en) 2004-02-03 2007-12-06 Collier Gregory R Methods and Compositions for Modulating Satiety
WO2006038070A2 (en) 2004-03-30 2006-04-13 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US7192500B2 (en) 2004-04-30 2007-03-20 Kimberly-Clark Worldwide, Inc. Process for making a garment including an absorbent assembly
US8030442B2 (en) 2004-09-16 2011-10-04 Morehouse School Of Medicine Treatment of injury to the brain by inhibition of acid sensing ion channels
CN105085678B (zh) * 2004-12-21 2019-05-07 阿斯利康公司 血管生成素-2的抗体及其应用
GEP20115226B (en) * 2005-04-26 2011-06-10 Pfizer P-cadherin antibodies
CN102585002A (zh) 2006-06-02 2012-07-18 瑞泽恩制药公司 人il-6受体的高亲和力抗体
EP2078732B1 (en) * 2006-07-10 2015-09-16 Fujita Health University Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry
WO2008007131A2 (en) * 2006-07-14 2008-01-17 Medical Research Council Treatment for demyelinating disease
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
US7598039B2 (en) 2007-01-30 2009-10-06 Academia Sinica Treatment of insulin resistance
DE602008002913D1 (de) 2007-04-03 2010-11-18 Ilegusavnid Genetics Resource Mit panikstörungen assoziierte amilorid-sensitive natriumkanäle
WO2008134659A2 (en) * 2007-04-27 2008-11-06 Zymogenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
EP2853897A1 (en) * 2008-05-08 2015-04-01 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
US20090291150A1 (en) 2008-05-21 2009-11-26 University Of Iowa Research Foundation Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity
FR2932091B1 (fr) 2008-06-06 2012-12-28 Centre Nat Rech Scient Effets analgesiques de la toxine peptidique apetx2
CA2742969A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
GB0922434D0 (en) * 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
CN102234316B (zh) * 2010-05-07 2014-01-29 中国人民解放军军事医学科学院毒物药物研究所 具有增强酸感受离子通道1a电流作用的多肽及其用途
EA028647B1 (ru) 2012-01-31 2017-12-29 Ридженерон Фармасьютикалз, Инк. Антитела к asic1 и их применение
US9371383B2 (en) 2012-01-31 2016-06-21 Regeneron Pharmaceuticals, Inc. Anti-ASIC1 antibodies and uses thereof

Also Published As

Publication number Publication date
EP2809681A1 (en) 2014-12-10
PT3453723T (pt) 2021-09-07
US10513557B2 (en) 2019-12-24
LT3453723T (lt) 2021-09-10
AU2013215254A1 (en) 2014-07-03
IL254416B (en) 2018-03-29
SI3453723T1 (sl) 2021-11-30
CL2014002019A1 (es) 2015-01-16
JO3547B1 (ar) 2020-07-05
IL233410A0 (en) 2014-08-31
US9150648B2 (en) 2015-10-06
WO2013116296A1 (en) 2013-08-08
AU2013215254B2 (en) 2017-08-31
HUE056335T2 (hu) 2022-02-28
EP3453723B1 (en) 2021-08-11
IN2014CN04645A (es) 2015-09-18
DK3453723T3 (da) 2021-09-13
NZ626242A (en) 2017-02-24
PL2809681T3 (pl) 2019-05-31
PH12014501613A1 (en) 2014-10-13
US20160002332A1 (en) 2016-01-07
CA2862332A1 (en) 2013-08-08
MX358518B (es) 2018-08-24
CN104093738B (zh) 2018-05-18
LT2809681T (lt) 2019-02-11
PH12014501613B1 (en) 2014-10-13
KR102111941B1 (ko) 2020-05-18
CN104093738A (zh) 2014-10-08
MX2014008541A (es) 2014-10-24
RS62454B1 (sr) 2021-11-30
JP2015508063A (ja) 2015-03-16
HK1199269A1 (en) 2015-06-26
HRP20190358T1 (hr) 2019-04-05
PL3453723T3 (pl) 2022-01-03
TW201335182A (zh) 2013-09-01
EP2809681B1 (en) 2018-12-05
US20130195878A1 (en) 2013-08-01
CO7020877A2 (es) 2014-08-11
EA028647B1 (ru) 2017-12-29
DK2809681T3 (en) 2019-03-11
JP6302844B2 (ja) 2018-03-28
UY34603A (es) 2013-07-31
IL254416A0 (en) 2017-11-30
CY1121368T1 (el) 2020-05-29
US20180222976A1 (en) 2018-08-09
HUE042531T2 (hu) 2019-07-29
KR20140125363A (ko) 2014-10-28
ES2886123T3 (es) 2021-12-16
EP3453723A2 (en) 2019-03-13
SG11201403222UA (en) 2014-07-30
BR112014018651A2 (pt) 2017-07-04
PT2809681T (pt) 2019-02-18
HRP20211541T1 (hr) 2021-12-24
MY168748A (en) 2018-11-30
EA201491452A1 (ru) 2014-11-28
RS58439B1 (sr) 2019-04-30
EP3453723A3 (en) 2019-04-10
CA2862332C (en) 2021-05-18
CY1124778T1 (el) 2022-11-25
TWI591073B (zh) 2017-07-11
ES2707599T3 (es) 2019-04-04
SI2809681T1 (sl) 2019-04-30

Similar Documents

Publication Publication Date Title
AR089852A1 (es) Anticuerpos anti-asic-1 y usos de los mismos
ECSP19025350A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
CY1117372T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους
CO7160093A2 (es) Anticuerpos anti-egfr y usos de los mismos
GT201500294A (es) Compuestos de biaril-amida como inhibidores de cinasa
UY35827A (es) Derivados de triazolopirazina como inhibidores de la proteína brd4
EA201500314A1 (ru) Лекарственные формы энзалутамида
CO6710907A2 (es) Anticuerpos que se unen específicamente a cd33 que son útiles en el tratamiento de trastornos de células mieloides y del síndrome mielodisplásico (msd)
CR20150067A (es) Pirazoles sustituidos como bloqueadores del canal de calcio tipo n
EA201692334A1 (ru) Кортикостероидные композиции для местного применения
BR112017028331A2 (pt) proteínas de fusão que se ligam a receptores fc humanos
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
GT201400179A (es) Compuestos de cromano sustituidos como moduladores del receptor sensible al calcio
CR20150070A (es) Pirrolopirazoles como bloqueadores del canal de calcio tipo n
BR112016028895A2 (pt) composições biofotônicas termofixas e usos destas
TR201907907T4 (tr) Benralizumab kullanarak astımlı hastalarda zorlu ekspiratuar hacmi arttırma yöntemleri.
BR112017027897A2 (pt) usos terapêuticos das formulações de berberina
CL2015003563A1 (es) Marcador para trastornos de la esfingomielinasa ácida y sus usos.
CY1116158T1 (el) Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
BR112014015578A2 (pt) composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide
NI201500172A (es) Composiciones farmacéuticas
CY1119117T1 (el) Δερμοπροστατευτικη και δερμο-εξισορροπητικη συνθεση
CY1118255T1 (el) Υποκατεστημενα 6-αμινο-νικοτιναμιδια τα οποια φερουν μια ομαδα που περιεχει οη ως διαμορφωτες των kcnq2/3
BR112018014771A2 (pt) composição compreendendo extrato de proteoglicanos de algas e seu uso
AR116616A1 (es) Variantes de anticuerpo anti-lap y usos de las mismas

Legal Events

Date Code Title Description
FG Grant, registration